We're changing our website design on 27 August 2017.

Idiopathic pulmonary fibrosis

The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).

Treatment with nintedanib and pirfenidone can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with IPF.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing nintedanib and pirfenidone.


Initial treatment

Make all initial applications for authority approval to prescribe nintedanib or pirfenidone for the treatment of IPF in writing and:

All applications must include a completed:

Initial grandfather treatment

For patients who received non PBS subsidised treatment for IPF with either nintedanib before 1 May 2017, or pirfenidone before 1 July 2017, make all initial grandfather applications in writing and:

All applications must include a completed:

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

We’re testing a new website design. Try it out and tell us what you think. Read more about changes to this site.

Page last updated: 1 July 2017

This information was printed Tuesday 22 August 2017 from humanservices.gov.au/health-professionals/enablers/idiopathic-pulmonary-fibrosis It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.